ALNYLAM PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expensed and Capitalized, Amount
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $87.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $87.73M, a 22.23% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $109.34M, a 134.57% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-06-30 was $112.81M, a 25.21% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-03-31 was $57.84M, a 25.32% increase year-over-year.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month |
|---|---|---|---|
| 2026-06-30 | $87.73M 10-Q · filed 2026-07-30 | $158.99M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $109.34M 10-Q · filed 2025-10-30 | $222.15M derived: sum of 2 quarters · filed 2026-07-30 | $279.99M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $112.81M 10-Q · filed 2026-07-30 | $170.65M 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $57.84M 10-Q · filed 2025-05-01 | ||
| 2024-09-30 | $46.61M 10-Q · filed 2025-10-30 | $136.71M derived: sum of 2 quarters · filed 2025-10-30 | $182.86M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $90.10M 10-Q · filed 2025-07-31 | $136.25M 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $46.16M 10-Q · filed 2025-05-01 | ||
| 2023-09-30 | $64.87M 10-Q · filed 2024-10-31 | $141.86M derived: sum of 2 quarters · filed 2024-10-31 | $183.00M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $76.99M 10-Q · filed 2024-08-01 | $118.13M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $41.14M 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |